Studies related to Blood Pressure and Fucoxanthin

The Effects Of Xanthigen In The Weight Management Of Obese Premenopausal Women With Non-alcoholic Fatty Liver Disease And Normal Liver Fat

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 151
Sex Female
Age Range 30-44, 45-64
Body Types Obese
Notes for this study:
16 weeks of using Xanthigen (300mg Pomegranate seed oil + 300mg seaweed extract giving 2.4mg fucoxanthin daily) was able to reduce bodyweight in obese non-diabetic females independent of the state of the liver, and decreased waist circumference only in the group with fatty liver, which was most likely secondary to reducing liver fat and liver enzymes in the group with NAFLD. All other parameters were seen in both the fatty liver groups as well as non-fatty liver groups (differentiation done at 11% liver fat)

Fucoxanthin also demonstrated a dose-dependent increasing of metabolic rate (REE) up to 8mg (highest tested), from 5.95kJ/min to 7.37kJ/min, the higher end of the scale correlating to an increase of 1915 ± 246 kJ/24 h relative to baseline. These differences only manifested after 16 weeks (were not acute), 1.6mg fucoxanthin daily was not deemed clinically effective (minimum dose 2.4mg established for significance)